Novel unboosted INSTI-based regimen generally well tolerated with no emergent resistance mutations.
The 2-drug regimen yielded 90% virologic success at Week 24 in patients with baseline HIV-1 RNA up to 500,000 copies/mL.
Encouraging long-term safety and efficacy data continue to support late-stage clinical development of long-acting injectable maintenance regimen.
The single-tablet regimen demonstrated a low cumulative rate of virologic rebound through 24 weeks, with few serious AEs and discontinuations due to AEs.
Efficacy of switch to INSTI-based regimen noninferior to continued PI treatment at Week 48 in older HIV-infected population with multiple risk factors for cardiovascular disease.
In addition to demonstrating comparable efficacy, DOR/3TC/TDF produced significantly fewer neuropsychiatric AEs and had a more favorable impact on fasting lipid levels in comparison with EFV/FTC/TDF.
Cabotegravir demonstrates good tolerability in preliminary study of use of this strategy for potential PrEP candidate.
HIV-1 RNA < 50 copies/mL in 89% vs 93% of patients at Week 48, with no treatment-emergent resistance mutations in either arm.
Lower risk of fracture was associated with cumulative efavirenz exposure, although no causal link found.
eGFR was significantly lower with zoledronic acid vs TDF switch, despite improvements in bone mineral density.